Definitive Contract 75N93018C00044
Award Date 9/10/18
Potential Completion Date 2/10/25
Potential Value $6.7M
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Australia
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
17
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a cost-type definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Virovax LLC, a minority-owned limited liability company, for an Adjuvant Development Program. The contract has a ceiling value of $9,273,316.19 and a period of performance through September 29, 2025. The contract was awarded on September 30, 2018 and does not utilize a set-aside designation. As NIAID is the funding agency, this award is likely supporting the...
- This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6.9 million definitive contract on September 30, 2023, to Institut De Formulation DES Vaccins (Ch) SA, operating as Vaccine Formulation Institute (Ch) LTD, a Switzerland-based nonprofit organization specializing in vaccine adjuvant development. Under this firm fixed-price contract, the awardee will conduct advanced development of a liposome-based saponin-containing adjuvant designed for use in pan-sarbecovirus vaccines....
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $10.3 million definitive cost-no-fee contract to the University of California, San Diego on September 30, 2024, to support the Vaccine Adjuvant Discovery Program (VADP). This five-year effort, which extends through September 2029, is being performed in La Jolla, California. The contract represents a bilateral modification to descope activities for fiscal year 2025 cost savings. No set-aside designation was used in this...
- This $599,526 Firm Fixed Price contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Enepret Incorporated, a for-profit manufacturer located in Lexington, Kentucky. The contract is for "Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune-Mediated Diseases" and supports NIAID's broader program goals related to "A More Durable and Universal Adjuvanted...
- This is a $10,725,896 federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Oregon Health & Science University (OHSU). The contract is for the Vaccine Adjuvant Discovery Program, which aims to identify novel adjuvant candidates that can enhance the efficacy of human vaccines. The contract is a definitive, cost-no-fee contract with a performance period ending on March 31, 2026. No set-aside was...
- The Department of Health and Human Services' National Institute of Allergy and Infectious Diseases (NIAID) awarded a $9,896,692 Vaccine Adjuvant Discovery Program (VADP) contract to the University of Montana. The 5-year contract, which has no set-aside designation, aims to identify, characterize, and advance novel synthetic adjuvants for use in combination with bacterial and fungal antigens to induce a safe and durable T-helper 17 (Th17) and/or Th17/Th1 immune response. The University of Montana...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $9.5M definitive contract to the University of Chicago on September 30, 2024, under the Vaccine Adjuvant Discovery Program (VADP). This cost-no-fee contract, which extends through September 29, 2029, supports research conducted at the university's Chicago, Illinois campus. The award represents a bilateral modification to descope the program for FY2025 cost savings, as indicated by the contract's stated objective of...
- Adjuvax LLC has been awarded a $600,000 firm fixed price definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to optimize the formulation of a virus-like particle adjuvant under a Small Business Innovation Research solicitation. The solicitation sought proposals across technical topics aligned with NIH and CDC missions to develop medical technologies and other solutions to advance public health. This opportunity was set aside for...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $10.2M cost-reimbursable contract to the University of California, Irvine (UCI) on September 1, 2022, for adjuvant comparison and characterization research. Under this definitive contract with a completion date of January 1, 2027, UCI will conduct comprehensive immune assessments comparing multiple adjuvants across various vaccine and antigen platforms. The work, to be performed in Irvine, California, supports NIAID's...